The BIO International Convention attracts 15,000+ biotechnology and pharma leaders for one week of intensive networking to discover new opportunities and promising partnerships. BIO brings together a wide spectrum of life science and application innovators in drug discovery, biomanufacturing, genomics, nanotechnology, and cell therapy.
Connect with us during BIO 2023 in Boston at the exhibit booth, in the partnering portal, or reach out to contact@lumanity.com
Meet with the below Lumanity staff at the conference:
- Kristin Abramo, Senior Consultant
- Jeffrey Bockman, PhD, Expert Advisor and Executive Vice President, Oncology
- Ginger Johnson, PhD, President, BioConsulting
- Bart Lombardi, Managing Director
- David Lomb, PhD, VP, Director of Consulting Operations and Autoimmune and Inflammatory Disease Co-Lead
- Danielle Marra, Principal
- Dominick Mastropoalo, Managing Director
- Tom Murtagh, President, Global Consulting
- Michael Rice, MS, MBA, Expert Advisor and Senior Vice President, Cell and Gene Therapy
- Ed Saltzman, Senior Scientific Advisor
- Joel Sandler, VP, Business Development and Marketing
- Zachary Sellman, Business Development Manager
Check out our Super Session at BIO
The Future of Combination Therapies for Cancer Treatment
June 7, 2023, 10:45am EST
Moderated by: Jeffrey Bockman, PhD, Expert Advisor, EVP, Oncology, Lumanity
Panelists:
- Li Mao, Vice President, General Manager of Research and Development and Chief Medical Officer, SciClone Pharmaceuticals
- Vassiliki (Vali) Papadimitrakopoulou, MD, MBA, VP, Clinical Development, Pfizer (invited)
- Emmett Schmidt, VP of Clinical Research & Early Development Oncology, Merck (invited)
- Jean-Charles Soria, MD, PhD, SVP & Oncology Therapeutic Area Head, Amgen (invited)
Immune checkpoint inhibitors have changed the way we treat cancer patients. However, only a fraction of cancer patients benefit from these treatments and further testing of combination therapies with checkpoint inhibitors is needed to broaden their utility and further improve outcomes. In this session, we will focus on the partnering strategies of leading biopharmacos in seeking collaborations for potential checkpoint inhibitor combinations. A particular focus will be on how radiation therapy in combination with checkpoint inhibitors may be beneficial in different clinical settings.